Journal for ImmunoTherapy of Cancer (Nov 2021)
Genomic alterations in biliary tract cancer predict prognosis and immunotherapy outcomes
- Jing Liu,
- Zhaoxia Wang,
- Yan Shi,
- Xue Li,
- Jun Zhou,
- Yongqian Shu,
- Yunpeng Liu,
- Jingdong Zhang,
- Xiaofeng Chen,
- Yang Shao,
- Fengjiao Zhao,
- Dongqin Zhu,
- Xiangcheng Li,
- Jieer Ying,
- Deqiang Wang,
- Jingrong Qiu,
- Haizhou Lou,
- Jiuwei Cui,
- Lanlan Pan,
- Jianyi Zhao,
- Shiqing Chen,
- Liuqing Zhu
Affiliations
- Jing Liu
- Oncology, Shanghai Jiao Tong University Medical School Affiliated Ruijin Hospital, Shanghai, China
- Zhaoxia Wang
- Oncology, Nanjing Medical University Second Affiliated Hospital, Nanjing, Jiangsu, China
- Yan Shi
- Oncology, Shanghai Jiao Tong University Medical School Affiliated Ruijin Hospital, Shanghai, China
- Xue Li
- Medical, Nanjing Geneseeq Technology Inc, Nanjing, China
- Jun Zhou
- Key Laboratory of Carcinogenesis & Translational Research, Peking University Cancer Hospital, Beijing, Beijing, China
- Yongqian Shu
- Oncology, Jiangsu Province Hospital and Nanjing Medical University First Affiliated Hospital, Nanjing, Jiangsu, China
- Yunpeng Liu
- Department of Medical Oncology, China Medical University First Hospital, Shenyang, Liaoning, China
- Jingdong Zhang
- Medical Oncology, Department of Gastrointestinal Cancer, Liaoning Cancer Institute and Hospital, Shenyang, Liaoning, China
- Xiaofeng Chen
- Oncology, Jiangsu Province Hospital and Nanjing Medical University First Affiliated Hospital, Nanjing, Jiangsu, China
- Yang Shao
- Medical, Nanjing Geneseeq Technology Inc, Nanjing, China
- Fengjiao Zhao
- Oncology, Jiangsu Province Hospital and Nanjing Medical University First Affiliated Hospital, Nanjing, Jiangsu, China
- Dongqin Zhu
- Medical, Nanjing Geneseeq Technology Inc, Nanjing, China
- Xiangcheng Li
- Hepatobiliary Center, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China
- Jieer Ying
- Abdominal Medical Oncology, Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Hangzhou, China
- Deqiang Wang
- Oncology, Jiangsu University Hospital, Jiangsu, China
- Jingrong Qiu
- Biological Therapy, Eastern Hepatobiliary Surgery Hospital, Shanghai, China
- Haizhou Lou
- Oncology, Zhejiang University School of Medicine Sir Run Run Shaw Hospital, Hangzhou, Zhejiang, China
- Jiuwei Cui
- Cancer Center, Jilin University First Hospital, Changchun, China
- Lanlan Pan
- Oncology, Jiangsu Province Hospital and Nanjing Medical University First Affiliated Hospital, Nanjing, Jiangsu, China
- Jianyi Zhao
- Oncology, Jiangsu Province Hospital and Nanjing Medical University First Affiliated Hospital, Nanjing, Jiangsu, China
- Shiqing Chen
- Medical, 3D Medicines Inc, Shanghai, China
- Liuqing Zhu
- Medical, Nanjing Geneseeq Technology Inc, Nanjing, China
- DOI
- https://doi.org/10.1136/jitc-2021-003214
- Journal volume & issue
-
Vol. 9,
no. 11
Abstract
No abstracts available.
